Eli Lilly（LLY）株式概要
イーライリリー・アンド・カンパニーは、米国、欧州、中国、日本、および世界各国において、ヒト用医薬品の創薬、開発、製造、販売を行っている。 詳細
LLY Community Fair Values
Create NarrativeSee what 838 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
Eli Lilly and Company 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$1,255.40 |
| 52週高値 | US$1,292.65 |
| 52週安値 | US$694.23 |
| ベータ | 0.51 |
| 1ヶ月の変化 | 4.96% |
| 3ヶ月変化 | 17.91% |
| 1年変化 | 80.55% |
| 3年間の変化 | 126.64% |
| 5年間の変化 | 378.59% |
| IPOからの変化 | 44,598.52% |
最新ニュース
Seeking Alpha • Aug 22
Eli Lilly: Shaking Off Competition From The Dethroned Novo Nordisk
Summary Eli Lilly has strengthened its global obesity drug market dominance, outpacing Novo Nordisk despite intensifying competition and pricing pressures. LLY's US market share has plateaued at 60–61%, but rising total prescriptions and global expansion underpin continued growth prospects. Valuation has compressed to just over 30x forward earnings, reflecting market expectations for growth deceleration and ongoing pricing competition. I maintain a Buy rating on LLY, supported by pipeline optionality, global consumer program expansion, and resilience amid normalization risks. Read the full article on Seeking Alpha
ナラティブ更新 • Aug 22
LLY: Obesity Franchise Concentration And Pricing Pressure Will Constrain Future Upside
Analysts have lifted the Eli Lilly fair value estimate from $899.73 to $982.09. Higher price targets reflect confidence that strong incretin demand, obesity franchise momentum and updated long-term guidance support a slightly higher assumed future P/E and profit margin, even with a modestly higher discount rate and tempered revenue growth inputs.Recent updates
Seeking Alpha • Aug 22
Eli Lilly: Shaking Off Competition From The Dethroned Novo Nordisk
Summary Eli Lilly has strengthened its global obesity drug market dominance, outpacing Novo Nordisk despite intensifying competition and pricing pressures. LLY's US market share has plateaued at 60–61%, but rising total prescriptions and global expansion underpin continued growth prospects. Valuation has compressed to just over 30x forward earnings, reflecting market expectations for growth deceleration and ongoing pricing competition. I maintain a Buy rating on LLY, supported by pipeline optionality, global consumer program expansion, and resilience amid normalization risks. Read the full article on Seeking Alphaナラティブ更新 • Aug 22
LLY: Obesity Franchise Concentration And Pricing Pressure Will Constrain Future Upside
Analysts have lifted the Eli Lilly fair value estimate from $899.73 to $982.09. Higher price targets reflect confidence that strong incretin demand, obesity franchise momentum and updated long-term guidance support a slightly higher assumed future P/E and profit margin, even with a modestly higher discount rate and tempered revenue growth inputs.分析記事 • Aug 08
Eli Lilly and Company Just Beat Revenue By 11%: Here's What Analysts Think Will Happen Next
Eli Lilly and Company ( NYSE:LLY ) just released its quarterly report and things are looking bullish. It was a positive...
ナラティブ更新 • Aug 08
LLY: GLP-1 Leadership And Retatrutide Progress Will Drive Balanced Outlook
Analysts have increased their fair value estimate for Eli Lilly stock from $1,270.37 to $1,297.31, reflecting higher Street price targets supported by strong Q2 incretin demand, GLP-1 franchise momentum, and updated long-term modeling around obesity and diabetes therapies. Analyst Commentary Recent Street research on Eli Lilly shows a clear focus on the company’s incretin and GLP-1 portfolio, with multiple firms adjusting price targets following Q2 results, obesity and diabetes trial updates, and refreshed long term models.ナラティブ更新 • Jul 25
LLY: GLP-1 Leadership And Retatrutide Data Will Shape Balanced Outlook
Eli Lilly's updated fair value estimate of $1,270.37, up from $1,243.43, reflects analysts' higher price targets that lean on expectations for stronger obesity and diabetes franchise contributions, incremental support from retatrutide data, and Q2 previews that factor in relatively higher revenue growth assumptions alongside slightly adjusted long term profit margins and future P/E multiples. Analyst Commentary Recent research on Eli Lilly points to a generally constructive stance from Wall Street, with multiple firms lifting price targets as they reassess the company's obesity and diabetes portfolio, retatrutide data, and Q2 earnings setup.ナラティブ更新 • Jul 10
LLY: GLP-1 Franchise And Retatrutide Data Will Support Balanced Future Outlook
Analysts have nudged their price targets on Eli Lilly higher, with fair value estimates moving from about $1,218.72 to roughly $1,243.43 as they point to resilient GLP-1 obesity and diabetes franchises, along with supportive recent data and previews around Zepbound, Mounjaro, Foundayo and retatrutide. Analyst Commentary Recent research updates on Eli Lilly show a cluster of higher price targets around the GLP-1 obesity and diabetes portfolio, with Zepbound, Mounjaro, Foundayo and retatrutide at the center of the discussion.ナラティブ更新 • Jun 24
LLY: Retatrutide Efficacy And GLP-1 Demand Will Support Balanced Outlook
Analysts have nudged up Eli Lilly's fair value estimate by about $4 to $1,218.72, reflecting modestly higher modeled revenue growth and a slightly richer future P/E multiple, supported by recent price target increases tied to retatrutide data and broader GLP-1 expectations. Analyst Commentary Recent commentary on Eli Lilly centers on how retatrutide data and GLP-1 demand expectations filter into valuation, growth assumptions, and execution risk.ナラティブ更新 • Jun 09
LLY: GLP-1 Leadership And Retatrutide Data Will Support Balanced Long-Term Outlook
Analysts have inched up their price targets on Eli Lilly, with several moving into the $1,250 to $1,350 range. They cite full Phase 3 retatrutide data that showed strong obesity and Type 2 diabetes outcomes, with what they view as manageable safety trade offs and a GLP-1 profile they say will be hard for rivals to match.ナラティブ更新 • May 26
LLY: GLP-1 Obesity Franchise Leadership Will Drive Long-Term Profitability
Analysts have nudged their price targets on Eli Lilly higher, with our fair value estimate moving by about $2 to $1,211 per share as they factor in expectations for stronger long-term profitability and GLP-1 leadership following positive retatrutide Phase 3 data, partly offset by more tempered revenue growth assumptions and a lower future P/E multiple. Analyst Commentary Recent research on Eli Lilly clusters around the same theme, retatrutide Phase 3 data supporting a premium valuation for the GLP-1 franchise, but with growing debate over how much future growth is already reflected in the stock.ナラティブ更新 • May 07
LLY: Obesity Pricing Pressure And Safety Headlines Will Shape Future Franchise Economics
Analysts have raised Eli Lilly's implied fair value from $883.99 to $899.73 after several firms increased their price targets by $1 to $50, citing confidence in the obesity and diabetes pipeline, Foundayo's regulatory progress, and clarifications around recent safety concerns. Analyst Commentary Recent research on Eli Lilly reflects a mix of enthusiasm around obesity and diabetes assets and a clearer, more cautious minority that is focused on how much optimism is already reflected in the stock.
ナラティブ更新 • Apr 20
LLY: Obesity And Diabetes Platform Will Support Premium Positioning Beyond 2030
Analysts have slightly raised their average price targets on Eli Lilly in recent weeks, citing supportive trial updates in obesity and diabetes, favorable comparisons to competing GLP-1 therapies, and regulatory progress that they say supports high but unchanged fair value estimates of around $1,500. Analyst Commentary Recent Street research around Eli Lilly has been active, with a cluster of price target moves, rating changes, and product specific notes that give you a clearer sense of how professionals are framing the risk and reward.ナラティブ更新 • Apr 06
LLY: Oral GLP-1 Launch And Capacity Expansion Will Drive Future Obesity Upside
Analysts have nudged Eli Lilly's price target slightly higher by $1, reflecting updated views on obesity and diabetes franchises following recent Foundayo approval commentary and comparative GLP-1 data. Analyst Commentary Recent research on Eli Lilly clusters around obesity and diabetes, pricing dynamics in GLP-1 therapies, and the implications of new product approvals and trial readouts for long term growth and valuation.
新しいナラティブ • Mar 25
Eli Lilly: A Pipeline-Driven Growth Story Trading 30% Below What the Business Is Actually Worth
Eli Lilly already runs one of the fastest-growing drug businesses on earth, and its most powerful drug is not even approved yet. WHERE THE STOCK SITS TODAY The current price is around $907 (25/03/2026).ナラティブ更新 • Mar 23
LLY: Obesity And Diabetes Franchise Strength Will Support Premium Positioning
Analysts have raised their price target for Eli Lilly to $1,500, citing updated models that reflect slightly stronger assumed revenue growth, a marginally higher profit margin profile, and continued confidence in the obesity and diabetes franchises following recent trial data and supportive sell side research. Analyst Commentary Recent research highlights a split view on Eli Lilly, with some bullish analysts leaning into the obesity and diabetes opportunity set, while at least one more cautious voice questions how much growth is already reflected in the share price.ナラティブ更新 • Mar 09
LLY: Obesity Drug Leadership And Pipeline Catalysts Will Sustain Premium Positioning
The updated analyst price target for Eli Lilly has increased to $1,490.52 from $1,429.89. Analysts highlight the obesity and GLP-1 franchise, premium valuations tied to weight loss leadership, and potential upside from pipeline and acquisition catalysts as key factors supporting this change.ナラティブ更新 • Feb 23
LLY: GLP-1 Obesity Leadership Will Drive Future Cardiometabolic And M&A Upside
Eli Lilly's analyst price targets have shifted higher, with our fair value estimate moving from $1,093.22 to $1,211.21, as analysts point to sustained GLP-1 obesity leadership, premium valuation support, and an expanding cardiometabolic pipeline as key drivers of their updated views. Analyst Commentary Recent Street research on Eli Lilly clusters around a few clear themes, with bullish analysts focusing on obesity leadership, cardiometabolic breadth, and M&A, while more cautious voices watch valuation and execution risk around the pipeline.ナラティブ更新 • Feb 08
LLY: Government Pricing Deals Will Compress Obesity Franchise Economics Going Forward
Analysts have raised their fair value estimate for Eli Lilly from US$770 to about US$884 per share, reflecting updated assumptions on long term obesity opportunities, recent price target increases across several firms, and steady expectations around margins and future P/E multiples. Analyst Commentary The latest batch of research on Eli Lilly revolves around its weight loss and cardiometabolic franchises, expectations for new product launches, and the implications of recent policy developments on pricing and access.分析記事 • Feb 07
Eli Lilly and Company (NYSE:LLY) Just Released Its Yearly Earnings: Here's What Analysts Think
Investors in Eli Lilly and Company ( NYSE:LLY ) had a good week, as its shares rose 2.0% to close at US$1,058 following...株主還元
| LLY | US Pharmaceuticals | US 市場 | |
|---|---|---|---|
| 7D | 6.1% | 5.4% | -1.2% |
| 1Y | 80.5% | 58.5% | 18.3% |
業界別リターン: LLY過去 1 年間で58.5 % の収益を上げたUS Pharmaceuticals業界を上回りました。
リターン対市場: LLY過去 1 年間で18.3 % の収益を上げたUS市場を上回りました。
価格変動
| LLY volatility | |
|---|---|
| LLY Average Weekly Movement | 4.9% |
| Pharmaceuticals Industry Average Movement | 9.2% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
安定した株価: LLY 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: LLYの 週次ボラティリティ ( 5% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1876 | 50,000 | Dave Ricks | www.lilly.com |
イーライ・リリー・アンド・カンパニーは、米国、欧州、中国、日本およびその他の国々において、ヒト用医薬品の研究開発、製造、販売を行っています。同社は、バサグラー、ヒューマログ、ヒューマログ・ミックス 75/25、 ヒューマログ U-100、ヒューマログ U-200、ヒューマログ ミックス 75/25、インスリン・リスプロ、インスリン・リスプロ・プロタミン、インスリン・リスプロ・ミックス 75/25、ヒューマリン、ヒューマリン 70/30、ヒューマリン N、ヒューマリン R、 糖尿病治療薬「ヒューマリン U-500」；2型糖尿病治療薬「ジャディアンス」、「ムンジャロ」、「トゥルーリシティ」；および肥満治療薬「ゼップバウンド」などを提供しています。また、胃がんまたは胃食道接合部腺がんの二次治療薬「サイラムザ」； 大腸がんおよび頭頸部がん治療薬「エルビトゥックス」；乳がん治療薬「インルリヨ」；慢性リンパ性白血病または小リンパ球性リンパ腫治療薬「ジェイピルカ」；転移性非小細胞肺がん（NSCLC）治療薬「レテヴモ」；古典型ホジキンリンパ腫治療薬「TYVYT」；および乳がん治療薬「ヴェルゼニオ」など、腫瘍学分野の製品も提供しています。 さらに、同社は免疫学領域の製品も提供しており、これには重度のアトピー性皮膚炎治療薬「エブグリス」、関節リウマチ、アトピー性皮膚炎、重度の円形脱毛症、およびCOVID-19治療薬「オルミアント」、 潰瘍性大腸炎治療薬「オムヴォ（Omvoh）」；および尋常性乾癬、乾癬性関節炎、強直性脊椎炎、非X線所見を伴う軸性脊椎関節炎治療薬「タルツ（Taltz）」が含まれます。さらに、片頭痛の予防および発作性群発頭痛治療薬「エムガリティ（Emgality）」、ならびにアルツハイマー病の対症療法薬「キスブラ（Kisubla）」も提供しています。 同社は、ジャディアンス（Jardiance）製品群に関してベーリンガーインゲルハイム・ファーマシューティカルズ社と、レブリキズマブに関してF. ホフマン・ラ・ロシュ社およびジェネンテック社と提携しているほか、エブグリス（Ebglyss）に関してアルミラル社と、 また、オルフォルグリプロンについては中外製薬株式会社と、非公開の単一遺伝子性腎疾患の治療法開発についてはアスキディアン・セラピューティクス社と、新たな治療法についてはバイオアークティックAB（publ）と戦略的提携を結んでいる。イーライ・リリー・アンド・カンパニーは1876年に設立され、インディアナ州インディアナポリスに本社を置いている。
Eli Lilly and Company 基礎のまとめ
| LLY 基礎統計学 | |
|---|---|
| 時価総額 | US$1.12t |
| 収益（TTM） | US$26.71b |
| 売上高(TTM) | US$79.67b |
41.9x
PER（株価収益率14.0x
P/SレシオLLY は割高か？
公正価値と評価分析を参照収益と収入
| LLY 損益計算書（TTM） | |
|---|---|
| 収益 | US$79.67b |
| 売上原価 | US$13.23b |
| 売上総利益 | US$66.44b |
| その他の費用 | US$39.73b |
| 収益 | US$26.71b |
直近の収益報告
Jun 30, 2026
次回決算日
Oct 29, 2026
| 一株当たり利益（EPS） | 29.97 |
| グロス・マージン | 83.40% |
| 純利益率 | 33.53% |
| 有利子負債／自己資本比率 | 162.1% |
LLY の長期的なパフォーマンスは？
過去の実績と比較を見る| Eli Lilly 配当日 | |
|---|---|
| 配当落ち日 | Aug 14 2026 |
| 配当支払日 | Sep 10 2026 |
| 配当落ちまでの日数 | 11 days |
| 配当支払日までの日数 | 16 days |
LLY 配当は確実ですか？
LLY 配当履歴とベンチマークを見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/08/24 16:21 |
| 終値 | 2026/08/21 00:00 |
| 収益 | 2026/06/30 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Eli Lilly and Company 28 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。54
| アナリスト | 機関 |
|---|---|
| David Toung | Argus Research Company |
| Emily Field | Barclays |
| Kerry Holford | Berenberg |